Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 7%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) traded up 7% on Tuesday . The stock traded as high as $16.39 and last traded at $16.22. 296,275 shares were traded during mid-day trading, a decline of 26% from the average session volume of 402,522 shares. The stock had previously closed at $15.16.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. HC Wainwright lifted their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Wednesday, March 6th. BMO Capital Markets boosted their price target on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an "outperform" rating in a report on Monday, March 4th. Canaccord Genuity Group boosted their price target on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a "buy" rating in a report on Monday, March 4th. Finally, Wedbush reissued an "outperform" rating and set a $18.00 price target (up previously from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $16.57.

Y-mAbs Therapeutics Stock Performance

The business has a fifty day moving average price of $15.78 and a 200 day moving average price of $10.30. The company has a market cap of $671.59 million, a price-to-earnings ratio of -31.31 and a beta of 0.74.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. The business had revenue of $23.36 million during the quarter, compared to analysts' expectations of $21.72 million. As a group, equities analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.43 EPS for the current year.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, SVP Vignesh Rajah sold 1,711 shares of the company's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total value of $28,282.83. Following the completion of the transaction, the senior vice president now owns 33,889 shares of the company's stock, valued at approximately $560,185.17. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 21.50% of the company's stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors have recently made changes to their positions in the stock. Trexquant Investment LP grew its position in shares of Y-mAbs Therapeutics by 417.5% in the 3rd quarter. Trexquant Investment LP now owns 76,585 shares of the company's stock valued at $417,000 after buying an additional 61,785 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Y-mAbs Therapeutics by 24.0% during the 3rd quarter. Acadian Asset Management LLC now owns 811,261 shares of the company's stock valued at $4,420,000 after purchasing an additional 157,173 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Y-mAbs Therapeutics by 208.3% during the 3rd quarter. GSA Capital Partners LLP now owns 137,299 shares of the company's stock valued at $748,000 after purchasing an additional 92,765 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Y-mAbs Therapeutics during the 4th quarter valued at about $34,000. Finally, Massachusetts Financial Services Co. MA boosted its position in shares of Y-mAbs Therapeutics by 258.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 82,131 shares of the company's stock valued at $448,000 after purchasing an additional 59,201 shares in the last quarter. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.